SCHEDULE 13G Filed 2026-10-07 Event — SEC 0001831942-26-000045 →

Commodore Capital LP → Sagimet Biosciences Inc. SGMT

Stake: — Shares: — Class: Series A Common Stock, $0.0001 par value per share

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

3 transactions

0 buys · 1 sales · 2 awards/exercises

Issuer Cluster

1 13D/G filings on this issuer

0 other filings besides this one

Filer Track Record

9 filings by this filer

8 other filings in the data moat

Short Interest · settle 2026-09-30

DTC 6.70

11,189,683 shares short · +9.0% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $1.04M

Point72 Asset Mgmt

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-08-11	Kemble George	director	Option exercise	9,751	$6.36	$62K
2026-08-11	Kemble George	director	Option exercise	10,455	$6.36	$66K
2026-08-11	Kemble George	director	Sale	20,206	$9.95	$201K

Other Filings by Commodore Capital LP

Filed	Form	Issuer	Stake	Shares
2026-10-01	SCHEDULE 13G	Surrozen, Inc./DE	—	—	view →
2026-09-02	SCHEDULE 13G	JATT III Acquisition Corp	—	—	view →
2026-08-17	SCHEDULE 13G	InflaRx N.V.	—	—	view →
2026-07-20	SCHEDULE 13G	Research Alliance Corp IV	—	—	view →
2026-06-18	SCHEDULE 13G	Avalo Therapeutics, Inc. AVTX	—	—	view →
2026-06-03	SCHEDULE 13G	EyePoint, Inc. EYPT	—	—	view →
2026-06-02	SCHEDULE 13G	Editas Medicine, Inc. EDIT	—	—	view →
2026-05-28	SCHEDULE 13G	Research Alliance Corp III RACC	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →